Trials / Completed
CompletedNCT00347919
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 189 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the ErbB2 protein.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pazopanib (GW786034) 400 mg | 400 mg administered orally once daily |
| DRUG | lapatinib (GW572016) 1500 mg | 1500 mg administered orally once daily. |
| DRUG | lapatinib (GW572016) 1000 mg | 1000 mg administered orally once daily |
| DRUG | pazopanib (GW786034) 800 mg | 800 mg administered orally once daily |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2008-08-01
- Completion
- 2015-03-01
- First posted
- 2006-07-04
- Last updated
- 2016-02-25
- Results posted
- 2011-02-21
Locations
84 sites across 16 countries: United States, Canada, France, Hungary, India, Israel, Malaysia, Mexico, Pakistan, Peru, Poland, Russia, Singapore, South Korea, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00347919. Inclusion in this directory is not an endorsement.